Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers (Q28081872)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers	scientific article

Statements

scholarly article

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25857348 AND SRC:MED&resulttype=core&format=json

5 March 2020

2 references

Europe PubMed Central

15 October 2020

Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers (English)

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25857348 AND SRC:MED&resulttype=core&format=json

5 March 2020

breast neoplasm

1 reference

15 October 2020

hormonal antineoplastic agent

1 reference

15 October 2020

2

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25857348 AND SRC:MED&resulttype=core&format=json

5 March 2020

Cristina Guarducci

4

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25857348 AND SRC:MED&resulttype=core&format=json

5 March 2020

5

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25857348 AND SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Ilenia Migliaccio

1

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25857348 AND SRC:MED&resulttype=core&format=json

5 March 2020

Christopher D Hart

3

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25857348 AND SRC:MED&resulttype=core&format=json

5 March 2020

language of work or name

1 reference

publication date

5 March 2015

5 references

13 March 2019

3 April 2019

17 June 2019

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25857348 AND SRC:MED&resulttype=core&format=json

5 March 2020

5 references

13 March 2019

3 April 2019

17 June 2019

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25857348 AND SRC:MED&resulttype=core&format=json

5 March 2020

15 October 2020

13

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25857348 AND SRC:MED&resulttype=core&format=json

5 March 2020

1

0 references

46

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25857348 AND SRC:MED&resulttype=core&format=json

5 March 2020

copyright license

Creative Commons Attribution

4 references

13 March 2019

3 April 2019

17 June 2019

15 October 2020

copyright status

0 references

on focus list of Wikimedia project

0 references

The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

20 March 2017

Comprehensive molecular portraits of human breast tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

20 March 2017

Combination anastrozole and fulvestrant in metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

20 March 2017

Molecular portraits of human breast tumours

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

20 March 2017

Repeated observation of breast tumor subtypes in independent gene expression data sets

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

20 March 2017

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

7 April 2017

A new era of improving progression-free survival with dual blockade in postmenopausal HR( ), HER2(-) advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

29 September 2017

Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

29 September 2017

PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

29 September 2017

Molecular profiling of single circulating tumor cells with diagnostic intention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

29 September 2017

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

29 September 2017

Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

29 September 2017

Luminal B breast cancer: molecular characterization, clinical management, and future perspectives

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

29 September 2017

Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

29 September 2017

Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

29 September 2017

Detection of cancer DNA in plasma of patients with early-stage breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

29 September 2017

Molecular tests as prognostic factors in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

29 September 2017

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

29 September 2017

The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

29 September 2017

Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal a

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

29 September 2017

PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

29 September 2017

PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

29 September 2017

PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

29 September 2017

Mechanisms of Endocrine Resistance in Breast Cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

29 September 2017

Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

29 September 2017

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

29 September 2017

Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

29 September 2017

Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

29 September 2017

Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

29 September 2017

Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4350905

29 September 2017

Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study.

1 reference

https://api.crossref.org/works/10.1186/S12916-015-0280-0

21 January 2018

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial

1 reference

https://api.crossref.org/works/10.1186/S12916-015-0280-0

21 January 2018

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1186/S12916-015-0280-0

21 January 2018

Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results

1 reference

https://api.crossref.org/works/10.1186/S12916-015-0280-0

21 January 2018

Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1186/S12916-015-0280-0

21 January 2018

Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study

1 reference

https://api.crossref.org/works/10.1186/S12916-015-0280-0

21 January 2018

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, mult

1 reference

https://api.crossref.org/works/10.1186/S12916-015-0280-0

21 January 2018

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1186/S12916-015-0280-0

21 January 2018

Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†.

1 reference

https://api.crossref.org/works/10.1186/S12916-015-0280-0

21 January 2018

Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study.

1 reference

https://api.crossref.org/works/10.1186/S12916-015-0280-0

21 January 2018

Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1186/S12916-015-0280-0

21 January 2018

Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer.

1 reference

https://api.crossref.org/works/10.1186/S12916-015-0280-0

21 January 2018

Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer

1 reference

https://api.crossref.org/works/10.1186/S12916-015-0280-0

21 January 2018

PIK3CA activating mutations: a discordant role in early versus advanced hormone-dependent estrogen receptor–positive breast cancer?

1 reference

https://api.crossref.org/works/10.1186/S12916-015-0280-0

21 January 2018

Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study

1 reference

https://api.crossref.org/works/10.1186/S12916-015-0280-0

21 January 2018

Erratum: Integrated genomic analyses of ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1186/S12916-015-0280-0

21 January 2018

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/25857348

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/25857348

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Polyendocrine Treatment in Estrogen Receptor–Positive Breast Cancer: A “FACT” Yet to Be Proven

1 reference

https://pubmed.ncbi.nlm.nih.gov/25857348

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25857348

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/S12916-015-0280-0

1 reference

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25857348 AND SRC:MED&resulttype=core&format=json

5 March 2020

Dimensions Publication ID

0 references

release_olazs2up5fe65lndh4xvw6ju7u

0 references

PMC publication ID

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25857348 AND SRC:MED&resulttype=core&format=json

5 March 2020

PubMed publication ID

2 references

Europe PubMed Central

PMC publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25857348 AND SRC:MED&resulttype=core&format=json

5 March 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28081872&oldid=2177471885"